Non-targeted siRNAs Curb Blood Vessel Growth | GenomeWeb

Non-targeted siRNAs suppress blood and lymphatic vessel growth in vivo as effectively as siRNAs directed against a key angiogenic growth factor as a result of immune response activation rather than an RNAi effect, researchers reported today.

These data, appearing in the Proceedings of the National Academy of Sciences, suggest that siRNAs inhibit both hemangiogenesis and lymphangiogenesis regardless of their sequence or targets, raising concerns over the possibility of unintended effects with certain RNAi drugs, the investigators add.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.